BioCentury
ARTICLE | Clinical News

PV-10: Completed Phase I enrollment

March 23, 2015 7:00 AM UTC

Provectus completed enrollment of 15 patients in an open-label, U.S. Phase I trial evaluating intratumoral PV-10. Patients will have surgery to remove their tumors about 7-14 days after receiving PV-1...